3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Breast Neoplasms
5
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Triple Negative Breast Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Interventions
Sunitinib
26
Everolimus
20
Bevacizumab
19
aldesleukin
18
Sorafenib
16
Nivolumab
16
Interleukin-2
14
pembrolizumab
13
Peripheral Blood Stem Cell Transplantation
13
fludarabine phosphate
12
Radiotherapy
12
Interferon-alpha
12
Cyclophosphamide
12
Radiosurgery
11
Filgrastim
11
Blood Specimen Collection
11
Ipilimumab
10
Gemcitabine
10
Axitinib
9
Surveys and Questionnaires
7
Gene Expression Profiling
7
Cryosurgery
7
temsirolimus
6
pazopanib
6
Surgical Procedures, Operative
6
durvalumab
5
cabozantinib
5
atezolizumab
5
Mycophenolic Acid
5
Immunohistochemistry
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Neoplasms
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled